Coya Therapeutics (COYA) Income from Continuing Operations (2022 - 2026)
Coya Therapeutics (COYA) reported Income from Continuing Operations of 7206990.0 for Q1 2026, up 1.37% on a YoY basis from 7109910.75 in Q1 2025, and up 15.88% sequentially from 8567956.0 in Q4 2025.
Coya Therapeutics (COYA) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Coya Therapeutics (COYA) has 5 years of Income from Continuing Operations data on file, last reported at 7206990.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 1.37% year-over-year to 7206990.0; the trailing twelve-month figure through Mar 2026 stood at 26731706.0 (up 13.13% YoY), and the FY2025 full-year result was 21303368.0, down 42.98% from the prior year.
- Income from Continuing Operations climbed to 7206990.0 in Q1 2026, from 8567956.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1700361.0 in Q1 2022 to a low of 12209369.0 in Q4 2024.
- A 5-year average of 5301644.53 and a median of 4530578.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations sank 220.46% in 2024 and soared 41.88% in 2025, its largest moves.
- Tracing COYA's Income from Continuing Operations over 5 years: stood at 3003518.0 in 2022, then retreated by 26.85% to 3809961.0 in 2023, then slumped by 220.46% to 12209369.0 in 2024, then grew by 29.82% to 8567956.0 in 2025, then advanced by 15.88% to 7206990.0 in 2026.
- Business Quant data shows COYA's Income from Continuing Operations at 7206990.0 in Q1 2026, 8567956.0 in Q4 2025, and 4861783.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.58 Bn | 466.79 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.18 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.80 Bn | 50.61 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Coya Therapeutics | 97.60 Mn | 46.87 Mn | - | -7.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.21 Mn |
| Dec 31, 2025 | -8.57 Mn |
| Sep 30, 2025 | -4.86 Mn |
| Jun 30, 2025 | -6.09 Mn |
| Mar 31, 2025 | -7.31 Mn |
| Dec 31, 2024 | -12.21 Mn |
| Sep 30, 2024 | -8.36 Mn |
| Jun 30, 2024 | -2.89 Mn |
| Mar 31, 2024 | -5.05 Mn |
| Dec 31, 2023 | -3.81 Mn |
| Sep 30, 2023 | -4.53 Mn |
| Jun 30, 2023 | -4.44 Mn |
| Mar 31, 2023 | -3.98 Mn |
| Dec 31, 2022 | -3.00 Mn |
| Sep 30, 2022 | -2.66 Mn |
| Jun 30, 2022 | -3.45 Mn |
| Mar 31, 2022 | -1.70 Mn |